For advanced EGFR-mutated NSCLC, epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) represent the standard of care as first-line treatment and help to reduce mortality and improve survival (2). Here, EGFR is linked to non-small cell lung carcinoma.